---
schema_version: "secwatch.filing_event.v1"
accession: "0001099800-26-000038"
form_type: "8-K"
ticker: "EW"
cik: "0001099800"
company_name: "Edwards Lifesciences Corp"
filed_at: "2026-07-23T20:29:00+00:00"
generated_at: "2026-07-23T20:30:22.049110+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Edwards Q2 sales up 13.6% to $1.74B; raises full-year sales and TAVR guidance

## Summary
- Q2 sales $1.74B (+13.6% YoY); adjusted EPS $0.78; gross margin 77.5%.
- TAVR sales $1.26B (+11.3% YoY); TMTT sales $195.9M (+47.3% YoY); Surgical $284M (+6.5% YoY).
- Raised FY constant currency sales growth guidance to 10-11% (from 9-11%); TAVR growth to 8-9% (from 7-9%).
- Reaffirmed adjusted EPS guidance $2.95-$3.05; Q3 guidance: sales $1.63-$1.71B, adj EPS $0.71-$0.77.
- Cash $2.9B, debt $600M; $1.5B remaining share repurchase authorization.

## SEC filing metadata
- accession: 0001099800-26-000038
- form_type: 8-K
- ticker: EW
- cik: 0001099800
- company_name: Edwards Lifesciences Corp
- filed_at: 2026-07-23T20:29:00+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000038/0001099800-26-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000038/ew-20260723.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001099800-26-000038
- JSON: https://secwatch.observer/filing/0001099800-26-000038.json
- Plain text: https://secwatch.observer/filing/0001099800-26-000038.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.